Clinical Trials Logo
  1. Home
  2. Acute Myeloid Leukemia, Adult
  3. NCT05988047

Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia, Adult Clinical Trial

Official title:
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia

Clinical Trial Summary

In this study, we aim to investigate the expression of CKLF like MARVEL transmembrane domain containing 6 (CMTM6) in leukemia cells of patients with acute myeloid leukemia (AML). We will use peripheral blood samples and assess CMTM6 expression by flow cytometry and Western Blot.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05988047
Study type Observational
Source University of Freiburg
Contact
Status Completed
Phase
Start date May 1, 2020
Completion date May 1, 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05133882 - A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML Phase 1/Phase 2
Active, not recruiting NCT05601726 - First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients Phase 1
Recruiting NCT06200441 - Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
Recruiting NCT04050280 - CLAG-GO for Patients With Persistent, Relapsed or Refractory AML Phase 2
Recruiting NCT06449482 - Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy Phase 1/Phase 2
Not yet recruiting NCT06252584 - Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients Phase 1
Terminated NCT03951961 - Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Phase 2
Enrolling by invitation NCT03902665 - Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 Phase 2
Not yet recruiting NCT06285136 - Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult Phase 2/Phase 3
Recruiting NCT05127798 - RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
Recruiting NCT05906914 - Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06199557 - A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients Phase 1/Phase 2
Recruiting NCT04752527 - Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features Phase 2
Recruiting NCT03766126 - Lentivirally Redirected CD123 Autologous T Cells in AML Phase 1
Recruiting NCT05674539 - Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome Phase 3
Enrolling by invitation NCT02985372 - Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia Phase 3
Recruiting NCT05703126 - Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML N/A
Recruiting NCT04240600 - Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay N/A
Terminated NCT04425655 - Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. Phase 2
Recruiting NCT04454580 - Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy